TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Sponsor

Janssen Sciences Ireland UC (Industry)

Overall Status

Completed

CT.gov ID

NCT01138605

Collaborator

(none)

Enrollment

Locations

Arms

85.4

Actual Duration (Months)

3.5

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibotec Pharmaceuticals and continue to benefit from using it, in countries where DRV is not yet commercially available for the pediatric patient, is not reimbursed or cannot be accessed through another source (like access program or government program).

Condition or Disease	Intervention/Treatment	Phase
HIV-1 Infections	Drug: Darunavir Drug: Ritonavir Drug: Ritonavir Drug: Darunavir Drug: Ritonavir Drug: Darunavir Drug: Darunavir Drug: Darunavir Drug: Ritonavir Drug: Darunavir Drug: Ritonavir Drug: Darunavir Drug: Darunavir Drug: Ritonavir Drug: Ritonavir	Phase 2

Detailed Description

This study has the aim to continue the provision of DRV and rtv to pediatric patients that continue to benefit from treatment with it after participation in any of three ongoing pediatric studies sponsored by Tibotec Pharmaceuticals. In addition, information on the safety of DRV and rtv in combination with other antiretroviral therapies will be assessed. At the baseline visit, inclusion and exclusion criteria will be checked to confirm eligibility. Once eligible, patients will continue treatment either on the once daily dose regimen (when coming from the TMC114-TiDP29-C230 study) or a twice daily regimen (when coming from the TMC114-C212 or TMC114-TiDP29-C228 studies). Assessments and visit frequency will take place as per local standard of care but are desirable every 3 months. The interval between two visits should not exceed 6 months. Pregnancy testing for girls having had their first menses is foreseen. In addition, it is desirable that testing includes efficacy assessments (immunology and plasma viral load) and laboratory safety assessments (hematology, biochemistry including pancreatic amylase (if available) or lipase and lipid analysis). Serious Adverse Events and certain selected Adverse Events will be collected. Treatment will be continued until one of the following criteria is met (whichever occurs first): Virologic failure, treatment limiting toxicity, loss to follow-up, withdrawal of consent or assent by the patient or withdrawal of consent by the caregiver, pregnancy, termination of the trial by the sponsor, when Darunavir becomes commercially available, is reimbursed or can be accessed through another source (as there are access program or government program) in the region the patient is living in. The sponsor advises participating centers to plan the study visits every 3 months but frequency will depend on local practice and standard of care. The sponsor has also foreseen in the study protocol a guidance on specific safety assessments to be performed as well as detailed instructions on how to deal with specific toxicities and undesirable effects. However local practice will prevail and the assessments performed may vary depending on the region the patient is participating in. Intake of study medication will happen once daily or twice daily, depending on what the patient took in the original pediatric trial. For the twice daily regimen, the regimen may be adjusted as the patient gains weight. The adult dosage regimen of 600/100 mg DRV/rtv may be administered as of 40 kg of body weight. Depending on the history of the patient, following dosages may be administered: DRV oral suspension (100mg DRV/ml), DRV tablets 75 mg, 150 mg, 600 mg, all for twice daily intake. DRV 400 mg for the once daily 800 mg intake (2 tablets per intake).DRV intake will be combined with rtv in oral suspension (80 mg rtv/ml), capsule or tablet (both 100 mg).

Study Design

Study Type:

Interventional

Actual Enrollment :

46 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Continued Access to DRV/Rtv in HIV-1 Infected Children and Adolescents (Rollover Patients From C212, C228, C230)

Actual Study Start Date :

Oct 13, 2010

Actual Primary Completion Date :

Nov 23, 2017

Actual Study Completion Date :

Nov 23, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 005 Darunavir 400 mg tablet intake of 2 tablets once daily in combination with ritonavir	Drug: Darunavir Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
Experimental: 006 Ritonavir Liquid formulation 80 mg/ml taken in combination with Darunavir	Drug: Darunavir 375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg Drug: Ritonavir Liquid formulation, 80 mg/ml, taken in combination with Darunavir
Experimental: 007 Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule	Drug: Darunavir 450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg Drug: Ritonavir 100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Experimental: 008 Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule	Drug: Darunavir 600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg Drug: Ritonavir 100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Experimental: 001 Darunavir Oral suspension 100 mg/ml 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg	Drug: Darunavir 400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
Experimental: 002 Darunavir 375 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 20 and 30 kg	Drug: Ritonavir Liquid formulation, 80 mg/ml, taken in combination with Darunavir Drug: Darunavir 375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
Experimental: 003 Darunavir 450 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 30 and 40 kg	Drug: Ritonavir 100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule Drug: Darunavir 450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
Experimental: 004 Darunavir 600mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight as of 40 kg	Drug: Ritonavir 100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule Drug: Darunavir 600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
Experimental: 009 Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.	Drug: Ritonavir Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.

Outcome Measures

Primary Outcome Measures

Safety and tolerability of DRV/rtv in combination with other ARVs will be summarized in terms of Mortality, all Serious Adverse Events,Adverse events leading to discontinuation and Adverse Events at least possibly related to the DRV treatment [Variable, up to 7 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

3 Years to 99 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient has completed the TMC114-C212, TMC114-TiDP29-C228 or TMC114-TiDP29-C230 study and continues to benefit from DRV
DRV is not commercially available, not reimbursed or cannot be accessed through another way
signed informed consent by parents/caregivers or assent by the patient is available prior to inclusion

Exclusion Criteria:

Any condition or active clinically significant disease (such as pancreas problems or cardiac problems) endangering the patient safety while being enrolled in the study
Previously demonstrated clinically significant allergy or hypersensitivity to the study medication
Pregnancy or breastfeeding female patients
Specific criteria will be applicable for girls having had their first menses and for girls and boys having reached the age of sexual activity

Contacts and Locations

Locations

	City	Country
1	Buenos Aires	Argentina
2	Ciudad Autonoma Buenos Aires	Argentina
3	Ribeirão Preto	Brazil
4	Rio De Janeiro	Brazil
5	Sao Paulo	Brazil
6	Paris	France
7	Chennai	India
8	Durban Kwazulu Natal	South Africa
9	Gauteng	South Africa
10	Johannesburg	South Africa
11	Esplugues De Llobregat	Spain
12	Kyiv	Ukraine
13	Birmingham	United Kingdom